Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions

AIDS

Volumn 27, Issue 4, 2013, Pages 579-589

  Bunupuradah, Torsak ^a   Duong, Trinh ^b   Compagnucci, Alexandra ^c   McMaster, Paddy ^d   Bernardi, Stefania ^e   Kanjanavanit, Suparat ^f   Rampon, Osvalda ^g   Faye, Albert ^h   Saïdi, Yacine ^c   Riault, Yoann ^c   De Rossi, Anita ^g   Klein, Nigel ⁱ   Ananworanich, Jintanat ^a,j,k   Gibb, Diana ^b  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c INSERM   (France)

^d NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f NAKORNPING HOSPITAL   (Thailand)

^g UNIVERSITY OF PADOVA   (Italy)

^h HÔPITAL ROBERT DEBRÉ   (France)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^k CHULALONGKORN UNIVERSITY   (Thailand)

more..

Author keywords

antiretroviral therapy; ART re initiation; HIV infected children; PTI; treatment interruption

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DEATH; DRUG ERUPTION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALTH CARE DISPARITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; PLANNED TREATMENT INTERRUPTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK FACTOR; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHILD; DISEASE PROGRESSION; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; FOLLOW-UP STUDIES; HIV SEROPOSITIVITY; HUMANS; MALE; RISK ASSESSMENT; RNA, VIRAL; THAILAND; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 84873408206     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835c1181     Document Type: Article

References (32)

1. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
2. Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-465.
3. Danel C,Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989.
4. Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS (London, England) 2007; 21:1957-1963.
5. El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Annals Internal Med 2008; 149:289-299.
6. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
7. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200:973-983.
8. Paediatric European Network for Treatment of AIDS. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010; 24:231-241.
9. Sefe D, Klein N, Mosconi I, Ricci E, Castro, H (nee Green), Jacobsen M, et al., on behalf of the PENTA Steering Committee. Immunologic and viral dynamics among HIV-infected children after planned treatment interruption: a substudy of the Paediatric European Network for Treatment of AIDS (PENTA) 11 trial. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 16-19 February 2010.
10. Ramos J, Melvin D, Medin G, Compagnucci A, Bleier J, Boscolo V, et al., on behalf of the PENTA Steering Committee. Neurocognitive and Quality of Life Outcomes in Children after Planned Treatment Interruptions: the randomized PENTA 11 trial. 19th Conference on Retroviruses and Opportunistic Infections, San Francisco, 5-8 March 2012.
11. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159:702-706.
12. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8:551-561.
13. Siberry GK, Patel K, Van Dyke RB, Hazra R, Burchett SK, Spector SA, et al. CD4R lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption. J Acquir Immune Defic Syndr 2011; 57:223-229.
14. Fortuny C, Noguera-Julian A, Alsina L, Bellido R, Sanchez E, Munoz-Almagro C, et al. Impact of CD4 T cell count on the outcome of planned treatment interruptions in early-treated human immunodeficiency virus-infected children. Pediatric Infect Dis J 2011; 30:435-438.
15. Castro H, Judd A, GibbDM, Butler K, Lodwick RK, van SighemA, et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011; 377:1580-1587.
16. Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, et al. Inferior clinical outcome of the CD4R cell countguided antiretroviral treatment interruption strategy in the SMART study: role of CD4R Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197:1145-1155.
17. Wald NJ, Simmonds M, Morris JK. Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. PloS One 2011; 6:e18742.
18. Gibb DM, Duong T, Leclezio VA, Walker AS, Verweel G, Dunn DT. Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Pediatric Infect Dis J 2004; 23:446-450.
19. Gibb DM, Newberry A, Klein N, de Rossi A, Grosch-Woerner I, Babiker A. Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet 2000; 355:1331-1332.
20. Chen RY, Westfall AO, Raper JL, Cloud GA, Chatham AK, Acosta EP, et al. Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. AIDS Res Human Retroviruses 2002; 18:909-916.
21. Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr 2005; 39:523-529.
22. Boschi A, Tinelli C, Ortolani P, Arlotti M. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4R cell counts in patients with chronic HIV infection. J Antimicrob Chemother 2006; 57:520-526.
23. Weinberg A, Dickover R, Britto P, Hu C, Patterson-Bartlett J, Kraimer J, et al. Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS (London, England) 2008; 22:2267-2277.
24. Lewis J, Walker AS, Castro H, De Rossi A, Gibb DM, Giaquinto C, et al. Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J Infect Dis 2012; 205:548-556.
25. Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving nonnucleoside reverse transcriptase inhibitor-basedhighly active antiretroviral therapy. Pediatric Infect Dis J 2009; 28:488-492.
26. Renner L, Prin M, Li FY, Goka B, Northrup V, Paintsil E. Time to and predictors of CD4R T-lymphocytes recovery in HIV-infected children initiating highly active antiretroviral therapy in Ghana. AIDS Res Treat 2011; 2011:1-9.
27. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
28. Baker JV, Neuhaus J, Duprez D, Cooper DA, Hoy J, Kuller L, et al. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS (London, England) 2011; 25:2133-2142.
29. Harrison L, Hamadache D, Bunupuradah T, Mazza A, Ramos J T, Flynn J, et al., on behalf of the PENTA 11 Trial Steering Committee. Adherence to ART and acceptability of planned treatment interruptions (PTI) in the PENTA 11 trial (treatment interruption in children with chronic HIV-infection). Poster number P 90. 1st International Workshop on HIV Pediatrics, Cape Town, SA, 17-18 July 2009.
30. DeJesus E, Ruane P, McDonald C, Garcia F, Sharma S, Corales R, et al. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials 2008; 9:103-114.
31. Saitoh A, Foca M, Viani RM, Heffernan-Vacca S, Vaida F, Lujan- Zilbermann J, et al. Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. Pediatrics 2008; 121:e513-e521.
32. Cotton M, Violari A, Gibb D, Otwombe K, Josipovic D, Panchia R, et al. Early ART followed by Interruption Is Safe and Is Associated with Better Outcomes than Deferred ART in HIVR Infants: Final Results from the 6-Year Randomized CHER Trial, South Africa. 19th Conference on Retroviruses and Opportunistic Infections, San Francisco, 5-8 March 2012.